ATE482722T1 - Therapeutische verwendung von anti-cs1- antikörpern - Google Patents

Therapeutische verwendung von anti-cs1- antikörpern

Info

Publication number
ATE482722T1
ATE482722T1 AT04810631T AT04810631T ATE482722T1 AT E482722 T1 ATE482722 T1 AT E482722T1 AT 04810631 T AT04810631 T AT 04810631T AT 04810631 T AT04810631 T AT 04810631T AT E482722 T1 ATE482722 T1 AT E482722T1
Authority
AT
Austria
Prior art keywords
antibodies
antagonists
subject
therapeutic use
present
Prior art date
Application number
AT04810631T
Other languages
English (en)
Inventor
Marna Williams
J Yun Tso
Nicholas F Landolfi
Gao Liu
Original Assignee
Facet Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Application filed by Facet Biotech Corp filed Critical Facet Biotech Corp
Application granted granted Critical
Publication of ATE482722T1 publication Critical patent/ATE482722T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04810631T 2004-03-29 2004-11-08 Therapeutische verwendung von anti-cs1- antikörpern ATE482722T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762104P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
PCT/US2004/037430 WO2005102387A2 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
ATE482722T1 true ATE482722T1 (de) 2010-10-15

Family

ID=35197500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04810631T ATE482722T1 (de) 2004-03-29 2004-11-08 Therapeutische verwendung von anti-cs1- antikörpern

Country Status (13)

Country Link
US (6) US7709610B2 (de)
EP (2) EP2301576B1 (de)
KR (1) KR101146775B1 (de)
CN (1) CN1960750B (de)
AT (1) ATE482722T1 (de)
AU (2) AU2004318675B2 (de)
BR (1) BRPI0418695A (de)
CA (1) CA2561065A1 (de)
DE (1) DE602004029399D1 (de)
IL (1) IL178121A (de)
MX (1) MXPA06011241A (de)
PL (1) PL2301576T3 (de)
WO (1) WO2005102387A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
ATE498010T1 (de) * 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
CA2624393C (en) 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20080095768A1 (en) * 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
PL2068930T3 (pl) * 2006-08-07 2013-02-28 Abbvie Biotherapeutics Inc Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego
EP3115049A1 (de) * 2006-08-07 2017-01-11 AbbVie Biotherapeutics Inc. Kombinationstherapien auf basis von anti-cs1-antikörpern zur behandlung von multiplem myelom
UA116614C2 (uk) 2006-11-02 2018-04-25 Дженентек, Інк. Антитіло до фактора d і його застосування
US20100152136A1 (en) * 2006-12-08 2010-06-17 Shaughnessy Jr John D TP53 Gene expression and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2316031B1 (de) 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 Biomarker zur Überwachung der Krebsbehandlung
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
EP2361263A1 (de) * 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Verwendung von anti-cs1-antikörpern zur behandlung seltener lymphome
EP2370579B1 (de) 2008-12-04 2017-03-29 CuRNA, Inc. Behandlung von erythropoetin (epo)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen epo
EP2446037B1 (de) 2009-06-26 2016-04-20 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
JP5728718B2 (ja) * 2009-12-28 2015-06-03 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体およびその使用
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
BR112012030179A8 (pt) 2010-05-27 2023-03-14 Merck Sharp & Dohme Polipeptídeo contendo fc
AU2012258907A1 (en) 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
EP2890715B1 (de) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Anti-pd-l1- und pd-l2-doppelbindende antikörper in form eines einzelnen wirkstoffes und verfahren zur verwendung
NO2760138T3 (de) 2012-10-01 2018-08-04
US9243059B2 (en) 2013-03-12 2016-01-26 Decimmune Therapeutics, Inc. Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury
EP3387898B1 (de) * 2013-03-15 2020-05-13 Mayo Foundation for Medical Education and Research Identifizierung und überwachung von monoklonalen immunglobulinen nach molekülmasse
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CA2910666A1 (en) 2013-05-03 2014-11-06 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells
EP2832747A1 (de) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP-Protein und Verwendungen davon
CA2919765C (en) 2013-08-01 2023-03-21 Universite Catholique De Louvain Anti-garp protein and uses thereof
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
WO2015035173A1 (en) * 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
WO2015069785A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
MX2016008098A (es) * 2013-12-20 2017-01-11 Hoffmann La Roche Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
WO2016018978A1 (en) 2014-07-29 2016-02-04 Mayo Foundation For Medical Education And Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
EP3212216A4 (de) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Varianten von interferon alpha2b
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
US10973914B2 (en) 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
SI3313528T1 (sl) 2015-06-29 2021-11-30 Bristol-Myers Squibb Company Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
CN108026164A (zh) 2015-09-24 2018-05-11 梅约医学教育与研究基金会 通过质谱鉴定免疫球蛋白游离轻链
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
EP3351271A1 (de) * 2017-01-23 2018-07-25 TheraPharm GmbH Radioimmunkonjugate zur verwendung bei der behandlung von krankheiten im zusammenhang mit knochenmark
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
JP6817492B2 (ja) 2017-08-07 2021-01-20 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
EP3681528A4 (de) 2017-09-13 2021-07-21 Mayo Foundation for Medical Education and Research Identifizierung und überwachung des apoptosehemmers von makrophagen
EP4257611A3 (de) 2018-05-18 2024-03-06 Glycotope GmbH Anti-muc1-antikörper
US11951131B2 (en) 2018-07-03 2024-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SLAMF7 chimeric antigen receptors
JP2022507718A (ja) 2018-11-20 2022-01-18 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
JP7520848B2 (ja) 2018-12-28 2024-07-23 スパークス・セラピューティクス・インコーポレイテッド 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
US20220390455A1 (en) 2019-11-05 2022-12-08 Bristol-Myers Squibb Company M-protein assays and uses thereof
US11801304B2 (en) 2020-02-19 2023-10-31 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
WO2022206941A1 (zh) * 2021-04-02 2022-10-06 克莱格医学有限公司 Cs1工程化细胞及其组合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO1999063088A2 (en) 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
WO2000047602A1 (en) 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
WO2003004622A2 (en) 2001-03-21 2003-01-16 Human Genome Sciences, Inc. Human secreted proteins
CA2284550A1 (en) 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US7465785B2 (en) 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
AU3750000A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020123617A1 (en) 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001266604A1 (en) 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
CA2421949A1 (en) * 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6478825B1 (en) 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR102028770B1 (ko) 2011-09-15 2019-10-04 컨버전트 인포메이션 테크놀로지스 게엠베하 로봇 프로그램의 자동 생성을 위한 시스템 및 방법
WO2013123099A1 (en) 2012-02-13 2013-08-22 Radius Engineering Inc. Reusable cartridge for injection molding

Also Published As

Publication number Publication date
AU2011200999B2 (en) 2012-05-31
EP1729803B1 (de) 2010-09-29
US8436146B2 (en) 2013-05-07
EP2301576A1 (de) 2011-03-30
US8444980B2 (en) 2013-05-21
US8088898B2 (en) 2012-01-03
AU2011200999A1 (en) 2011-03-31
DE602004029399D1 (de) 2010-11-11
AU2004318675B2 (en) 2011-06-16
AU2004318675A1 (en) 2005-11-03
MXPA06011241A (es) 2007-01-16
EP1729803A4 (de) 2007-08-08
US8349330B2 (en) 2013-01-08
US20120064068A1 (en) 2012-03-15
WO2005102387A3 (en) 2006-03-09
BRPI0418695A (pt) 2007-06-12
US8461306B2 (en) 2013-06-11
CN1960750B (zh) 2011-06-29
US20120064067A1 (en) 2012-03-15
KR20070011412A (ko) 2007-01-24
KR101146775B1 (ko) 2012-05-21
EP1729803A2 (de) 2006-12-13
CN1960750A (zh) 2007-05-09
IL178121A (en) 2016-12-29
PL2301576T3 (pl) 2013-02-28
US20090246852A1 (en) 2009-10-01
IL178121A0 (en) 2008-03-20
US20060024296A1 (en) 2006-02-02
CA2561065A1 (en) 2005-11-03
US7709610B2 (en) 2010-05-04
US20120070440A1 (en) 2012-03-22
EP2301576B1 (de) 2012-09-19
WO2005102387A2 (en) 2005-11-03
US20120064069A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
LU93274I2 (fr) Elotuzumab
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
ATE470676T1 (de) Anti-vegf-2 antikörper
EA200100822A1 (ru) Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
BRPI0622074A8 (pt) Anticorpos de pdgfralfa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties